DCPXF (DanCann Pharma AS) Stock Based Compensation: $0.00 Mil (TTM As of Sep. 2025)


DCPXF DanCann Pharma AS DCPXF
20 GF Score
Price $10.00
GF Value $37.14
! 3 Warning Signs
View Full Analysis

What is DanCann Pharma AS Stock Based Compensation?

DanCann Pharma AS DCPXF 20 Stock Based Compensation is $0.00 Mil as of Sep. 2025. GuruFocus rates DCPXF with a GF Score™ of 20/100 and a GF Value™ of $37.14. The stock has 3 warning signs investors should review.

DanCann Pharma AS's Stock Based Compensation for the three months ended in Sep. 2025 was $0.00 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 was $0.00 Mil.

DanCann Pharma AS Stock Based Compensation Related Terms

DanCann Pharma AS Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for DanCann Pharma AS's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DanCann Pharma AS Stock Based Compensation Chart

DanCann Pharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Stock Based Compensation
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

DanCann Pharma AS Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
DCPXF
20GF Score
DanCann Pharma AS DCPXF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DanCann Pharma AS Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

What does a Stock Based Compensation of $0.00 Mil mean?
DanCann Pharma AS (DCPXF) has a Stock Based Compensation of $0.00 Mil as of Sep. 2025. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DanCann Pharma AS and its competitors.
Is DanCann Pharma AS's Stock Based Compensation too high?
DanCann Pharma AS's current Stock Based Compensation is $0.00 Mil. Overall, DanCann Pharma AS has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does DanCann Pharma AS's Stock Based Compensation compare to ZTS and UTHR?
DanCann Pharma AS's Stock Based Compensation of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for DanCann Pharma AS and its competitors. DanCann Pharma AS's current Stock Based Compensation is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DanCann Pharma AS stock overvalued right now?
DanCann Pharma AS (DCPXF) has a current Stock Based Compensation of $0.00 Mil. The stock's GF Value™ is $37.14, compared to a current price of $10.00 — trading 73.1% below its estimated fair value. The current Stock Based Compensation is $0.00 Mil. DanCann Pharma AS's overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For DanCann Pharma AS (DCPXF), the current Stock Based Compensation is $0.00 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DanCann Pharma AS (DCPXF) Overvalued in 2026?

Based on GuruFocus' analysis, DanCann Pharma AS stock appears to be undervalued. The current stock price of $10.00 is trading 73.1% below its estimated GF Value™ of $37.14.

Key valuation signals for DCPXF:

  • Stock Based Compensation: $0.00 Mil
  • GF Value™: $37.14 vs. price of $10.00 (73.1% below fair value)
  • GF Score™: 20/100 with 3 warning signs

No single metric tells the full story. See the DCPXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DanCann Pharma AS Business Description

Address Rugvaenget 5, Ansager, DNK, DK-6823
DanCann Pharma AS is a Danish biopharmaceutical Company powered by cannabinoids. DanCann Pharma is a licensed production and distribution Company. The company is focused on discovering, developing, manufacturing, and commercializing novel cannabinoid therapeutics for a broad range of diseases.
20GF Score

Get the complete analysis for DCPXF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$10.00
Price
$37.14
GF Value